ESMO 2023 – David C. Currow

David C. Currow highlights the encouraging results of two Phase 3 randomized trials that investigated a ghrelin antagonist to combat cachexia in NSCLC patients. He also provides an overview of the recent advancements in integrating palliative care for cancer patients, and addresses the ongoing challenges that we still face in terms of end-of-life care in everyday practice.

Here is the full ESMO 2023 Lung Cancer report.